Jazz grows cannabinoid manufacturing ambitions with new $100M plantnews2022-03-25T14:55:46+00:00March 25th, 2022|Fierce Pharma|
Gilead, after 11% revenue increase in 2021, rewards CEO O’Day with $19.2M pay packagenews2022-03-25T13:42:17+00:00March 25th, 2022|Fierce Pharma|
Gilead, after 11% revenue increase in 2021, rewards CEO Daniel O’Day with $19.2M pay packagenews2022-03-25T13:42:17+00:00March 25th, 2022|Fierce Pharma|
Bristol Myers Squibb, Merck hit setback in bid to expand Reblozyl’s anemia nodnews2022-03-25T12:25:10+00:00March 25th, 2022|Fierce Pharma|
AAD 2022: Eli Lilly plugs Olumiant 52-week data as JAK inhibitor looks to fill out label with industry-first alopecia nodnews2022-03-25T11:03:28+00:00March 25th, 2022|Fierce Pharma|
Moderna weighs private market debut for COVID shot as federal funding floundersnews2022-03-25T09:25:07+00:00March 25th, 2022|Fierce Pharma|
Fierce Pharma Asia—Chinese biotech’s Pfizer trade secret suit; Lilly, Innovent’s FDA rebuff; Aurobindo’s New Jersey closurenews2022-03-25T08:44:01+00:00March 25th, 2022|Fierce Pharma|
After layoffs, Gilead to build NJ hub that will employ up to 500news2022-03-24T20:49:56+00:00March 24th, 2022|Fierce Pharma|
After Supreme Court win, Merck prevails against 500 Fosamax cases: reportnews2022-03-24T18:31:01+00:00March 24th, 2022|Fierce Pharma|
Meeting the cold chain challenges of remote locationsnews2022-03-24T16:12:54+00:00March 24th, 2022|Fierce Pharma|
